Clinical Trials on B-cell NHL

Total 34451 results

RenJi Hospital

Recruiting

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Emory University
National Cancer Institute (NCI); Novartis; Secura Bio, Inc.

Recruiting

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Weprom

Recruiting

Secondary Prognostic Index in RefrActory Lymphoma (SPiRAL)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

France
Institute of Hematology & Blood Diseases Hospital

Recruiting

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma

China
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
Fondazione Italiana Linfomi ONLUS
Janssen Pharmaceutica; Janssen-Cilag Ltd.; Centro di Riferimento per l'Epidemiologia...

Completed

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (FIL_VERAL12)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-cell Lymphoma Refractory

Italy
Fondazione Italiana Linfomi ONLUS

Completed

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL (ANZINTER3)

Diffuse Large B Cell Lymphoma (DLBCL) | Elderly Patients (>65 Years)

Italy
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
Adicet Bio, Inc

Recruiting

A Phase 1 Study of ADI-001 in B Cell Malignancies (GLEAN-1)

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Adicet Bio, Inc

Enrolling by invitation

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

China
Heidelberg University
Ludwig-Maximilians - University of Munich; Universitätsmedizin Mannheim; Diakonie... and other collaborators

Unknown

Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) (PERLL)

B-Cell Chronic Lymphocytic Leukemia | B-Cell Non-Hodgkin's Lymphoma | Immunocytoma/Morbus Waldenström
The First Affiliated Hospital with Nanjing Medical...

Unknown

Trial of DA-EPOCH Regimen for NHL With HLH

NHL With Hemophagocytic Lymphohistiocytosis

China
University Hospital, Montpellier

Not yet recruiting

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? (CARTROG)

Diffuse Large B Cell Lymphoma
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma

United States
Yan Zhang, MD
Peking University First Hospital; Chinese PLA General Hospital; Peking University...

Recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Lars Møller Pedersen
Zealand University Hospital; Weill Medical College of Cornell University; Herlev... and other collaborators

Not yet recruiting

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Diffuse Large B Cell Lymphoma
He Huang
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Huazhong University of Science and Technology

Recruiting

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Diffuse Large B Cell Lymphoma

China
AstraZeneca
Hospital Israelita Albert Einstein

Recruiting

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Diffuse Large B Cell Lymphoma

Brazil
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Diffuse Large B Cell Lymphoma

China
Zhao Weili

Not yet recruiting

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Recruiting

A Combination Study of CAR-T Therapy in r/r B-NHL

Diffuse Large B Cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Diffuse Large B Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma
University of Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna; Associazione Italiana per...

Recruiting

Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy (MicroCar)

Diffuse Large B Cell Lymphoma

Italy
Centre Henri Becquerel

Not yet recruiting

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells (RT-CAR)

Diffuse Large B Cell Lymphoma

France
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
Incyte Corporation

Recruiting

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) (firmMIND)

Diffuse Large B-Cell Lymphoma | Large B-Cell Lymphoma

Croatia, Serbia, Czechia, Finland, Israel, Romania, Denmark, Hungary, Ireland, Poland, Turkey, Bulgaria, Norway, United Kingdom
Ruijin Hospital
Shanxi Province Cancer Hospital; The First Affiliated Hospital of Anhui Medical... and other collaborators

Recruiting

Genotype-guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (R-ICE+X)

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Diffuse Large B Cell Lymphoma

China
MorphoSys AG
Iqvia Pty Ltd

Recruiting

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND)

Diffuse Large B-cell Lymphoma

United States
Weprom

Recruiting

Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line (PHARAOM)

Diffuse Large B Cell Lymphoma

France
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Diffuse Large B-cell Lymphoma

China
Nanfang Hospital of Southern Medical University

Not yet recruiting

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Wuhan University

Recruiting

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Wuhan University

Recruiting

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Karyopharm Therapeutics Inc

Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Netherlands, New Zealand, Poland, Serbia, Spain
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Hoffmann-La Roche

Active, not recruiting

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Israel, Spain, Korea, Republic of, Poland, Taiwan
MorphoSys AG

Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)

Diffuse Large B-cell Lymphoma

Germany, France, Hungary, Italy, Spain, United States, Austria, Czechia, Australia, Israel, Korea, Republic of, Turkey, Taiwan, Argentina, Canada, Colombia, Ireland, Japan, Malaysia, New Zealand, Philippines, Poland, Romania, Russian... and more
Henan Cancer Hospital

Active, not recruiting

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China

Clinical Trials on B-cell NHL

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations